전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved318 programs
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®808 (XmAb®808)

Head and Neck Squamous Cell Carcinoma; Melanoma Excluding Uveal Melanoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+1
Trials 1Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#ClinicalStageIVCutaneousMelanoma+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing 302 HospitalPhase 2

allogeneic NK cells therapy (allogeneic NK cells therapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleTongji HospitalPreclinical

apatinib plus camrelizumab (apatinib plus camrelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Preclinical#monoclonal-antibody#Tongji
Trials 1Status Recruiting
CGTLimited DatastaleAeon Therapeutics (Shanghai) Co…Phase 1

autologous ET1402L1-CART cells (autologous ET1402L1-CART cells)

Hepatocellular Carcinoma; Liver Cancer · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

cTACE+Atirizumab+Bevacizumab (cTACE+Atirizumab+Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

cisplatin, vinorlebine, cetuximab (cisplatin, vinorlebine, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

cisplatine, etoposide, cetuximab (cisplatine, etoposide, cetuximab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
ADCLimited DatastaleAstellasPreclinical

pembrolizumab (Keytruda, enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma)

Advanced Upper Tract Urothelial Carcinoma · Advanced Upper Tract Urothelial Carcinom

#AdvancedUpperTractUrothelialCarc#ADC#Preclinical#antibody-drug-conjugate#Astellas
Trials 1Status Active
AntibodyLimited DatastaleArrys TherapeuticsPhase 2

pembrolizumab (Keytruda, grapiprant and pembrolizumab)

Non-small Cell Lung Cancer Adenocarcinoma · Non-small Cell Lung Cancer Adenocarcinom

#Non-smallCellLungCancerAdenocarc#Antibody#Phase2#monoclonal-antibody#Arrys
Trials 1Status Discontinued
CGTLimited DatastaleBellicum PharmaceuticalsPhase 1

iC9.GD2.CAR.IL-15 T Infusion (iC9.GD2.CAR.IL-15 T Infusion)

Lung Cancer; Small Cell Lung Carcinoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastalePeking Union Medical CollegePhase 2

iparomlimab + tuvonralimab (iparomlimab + tuvonralimab)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#monoclonal-antibody#PrecisionTherapy+1
Trials 1Status Recruiting
AntibodyLimited DatastalePeking Union Medical CollegePhase 2

ivonescimab + investigator-choice platinum doublet+ (ivonescimab + investigator-choice platinum doublet+)

Salivary Gland Carcinoma; Precision Therapy · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#monoclonal-antibody#PrecisionTherapy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleVaccinex Inc.Phase 2

pembrolizumab (Keytruda, pepinemab + pembrolizumab)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) · Recurrent/Metastatic Squamous Cell Carci

#RecurrentMetastaticSquamousCellC#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

toripalimab + cetuximab + platinum (three cycles, three cycles (toripalimab + cetuximab + platinum))

Locally Advanced Hypopharyngeal Carcinoma · Locally Advanced Hypopharyngeal Carcinom

#LocallyAdvancedHypopharyngealCar#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

treme (tremelimumab, tremelimumab (treme))

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck · Advanced Solid Tumors & Metastatic Squam

#AdvancedSolidTumorsMetastaticSqu#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

tremelimumab+MEDI4736 (tremelimumab+MEDI4736)

Metastatic Pancreatic Ductal Adenocarcinoma · Metastatic Pancreatic Ductal Adenocarcin

#MetastaticPancreaticDuctalAdenoc#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Active

16 / 16 pages

← PreviousNext →